COMMUNIQUÉS West-GlobeNewswire

ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
06/01/2026
PRINCETON, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 44 th Annual J.P. [...]
Alumis Announces Proposed Public Offering of Common Stock
06/01/2026
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated [...]
OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
06/01/2026
MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK ) announced today that management will be participating in the 44 th Annual J.P. Morgan Healthcare Conference, being held January 12-15, 2026, at [...]
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results
06/01/2026
Conference call and webcast to be held at 8 a.m. ET on January 7, 2026 BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel [...]
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
06/01/2026
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Carlsmed aprevo® Lumbar 2-year Data Published in Global Spine Journal
06/01/2026
CARLSBAD, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the publication of a new retrospective cohort study in Global Spine Journal demonstrating [...]
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
06/01/2026
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
Bright Minds Biosciences Announces Launch of US$100 Million Public Offering
06/01/2026
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”) announces the launch of a public offering of common shares in the capital of the [...]
Transactions of Managers and Closely Associated Persons
06/01/2026
Attached is a copy of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of shares in [...]
Transactions of Managers and Closely Associated Persons
06/01/2026
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of 7,007,321 shares [...]
Beacon Behavioral Partners Enters 2026 Poised for Continued Growth Following Regional Expansion and Senior Leadership Additions
06/01/2026
Pivotal Investments in People, Technology and Infrastructure Position the Organization for Accelerated Impact BATON ROUGE, La., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Beacon Behavioral Partners (BBP) , one of the nation’s [...]
SOUND Behavioral Health Chosen for Washington’s CCBHC Pre-Certification Cohort
06/01/2026
As part of the state’s pre-certification cohort, SOUND is leading the shift toward integrated, equitable, and outcomes-driven behavioral health services. SEATTLE, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SOUND Behavioral [...]
LifeLabs Named Canada’s Most Trusted Health Diagnostic Brand for Fourth Year in a Row
06/01/2026
This recognition highlights LifeLabs commitment to empowering healthier Canadians Toronto, Ontario, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LifeLabs, Canada’s leading provider of laboratory diagnostics, has been voted by [...]
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
06/01/2026
Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the new standard of [...]
GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N
06/01/2026
Phase 1 results confirm investigational drug-candidate G1090N has a favorable safety and tolerability profile, supporting further clinical evaluation Compelling anti-inflammatory activity of G1090N was evidenced through [...]
GENFIT : Profil de sécurité favorable en Phase 1 et forte activité anti-inflammatoire pour G1090N, actif clé dans l’ACLF
06/01/2026
Les résultats de Phase 1 confirment que le candidat-médicament expérimental G1090N présente un profil de sécurité et de tolérabilité favorable, justifiant la poursuite de son évaluation clinique Une activité anti- [...]
Clinical Neurology Specialists Partnering with Leading International Nonprofit to Accelerate Alzheimer’s Research in Las Vegas
06/01/2026
Collaboration to Improve Access to Study for Alzheimer’s Disease LAS VEGAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Today, Global Alzheimer’s Platform Foundation ® (GAP) and Clinical Neurology Specialists (CNS) announced [...]
Ipsen – Half year statement – 2025 12 31
06/01/2026
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF PARIS, 06 JANUARY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that under the liquidity agreement entrusted by IPSEN S.A. to NATIXIS [...]
Ipsen - Bilan semestriel - 31 12 2025
06/01/2026
Bilan semestriel du contrat de liquidité entre IPSEN et NATIXIS ODDO BHF PARIS, FRANCE, 06 JANVIER 2026 - Ipsen (Euronext : IPN ; ADR : IPSEY) annonce aujourd'hui qu’au titre du contrat de liquidité confié par IPSEN S.A [...]

Pages